Immunological assay for assessing the efficacy of glatiramer acetate (Copaxone) in multiple sclerosis

A pilot study

Cinthia Farina, Stefan Wagenpfeil, Reinhard Hohlfeld

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Recently we described an enzyme-linked immunoadsorbent spot (ELISPOT) assay allowing us to define an immunological response profile observed in multiple sclerosis patients treated with Copaxone (glatiramer acetate; GA) but not untreated subjects [4]. The profile encompasses three criteria, a) reduced proliferative response to GA (as observed with a standard primary proliferation assay); b) strong in vitro activation of interferon-γ-producing T cells at high concentrations of GA (as detected by interferon-γ ELISPOT); and c) activation of interleukin-4-producing T cells over a wider range of concentrations of GA (as detected by interleukin-4 ELISPOT). It is at present unknown whether the immunological response to GA correlates with the clinical response. To address this question we performed the pilot study reported here. We asked the major German multiple sclerosis centres to send us blood samples from all GA-treated patients who were going to discontinue treatment because of treatment failure. The clinical non-responders either had an unchanged or increased exacerbation rate, or developed a secondary progressive course during GA treatment. Over more than one year, we prospectively collected 9 samples from clinical non-responders. We compared the immune response to GA of peripheral blood mononuclear cells from the 9 clinical non-responders with 15 clinical responders, using a standard proliferation assay combined with ELISPOT assays for detection of interferon-γ and interleukin-4 secreting cells. Thirteen (86%) of the 15 clinical responders met at least 2 of the immunological response criteria mentioned above. In contrast, only 2 (22%) of the 9 clinical nonresponders met two of the immunological criteria (p = 0.0006). We conclude that the ELISPOT assay may provide a promising additional tool for monitoring the treatment response in multiple sclerosis patients treated with GA.

Original languageEnglish
Pages (from-to)1587-1592
Number of pages6
JournalJournal of Neurology
Volume249
Issue number11
DOIs
Publication statusPublished - 2002

Fingerprint

Immunosorbents
Multiple Sclerosis
Interleukin-4
Interferons
Enzymes
T-Lymphocytes
Treatment Failure
Blood Cells
Therapeutics
Glatiramer Acetate

Keywords

  • Elispot assay
  • Glatiramer acetate
  • Multiple sclerosis

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Immunological assay for assessing the efficacy of glatiramer acetate (Copaxone) in multiple sclerosis : A pilot study. / Farina, Cinthia; Wagenpfeil, Stefan; Hohlfeld, Reinhard.

In: Journal of Neurology, Vol. 249, No. 11, 2002, p. 1587-1592.

Research output: Contribution to journalArticle

@article{18f22a77eaba43f0bd2a60a625770994,
title = "Immunological assay for assessing the efficacy of glatiramer acetate (Copaxone) in multiple sclerosis: A pilot study",
abstract = "Recently we described an enzyme-linked immunoadsorbent spot (ELISPOT) assay allowing us to define an immunological response profile observed in multiple sclerosis patients treated with Copaxone (glatiramer acetate; GA) but not untreated subjects [4]. The profile encompasses three criteria, a) reduced proliferative response to GA (as observed with a standard primary proliferation assay); b) strong in vitro activation of interferon-γ-producing T cells at high concentrations of GA (as detected by interferon-γ ELISPOT); and c) activation of interleukin-4-producing T cells over a wider range of concentrations of GA (as detected by interleukin-4 ELISPOT). It is at present unknown whether the immunological response to GA correlates with the clinical response. To address this question we performed the pilot study reported here. We asked the major German multiple sclerosis centres to send us blood samples from all GA-treated patients who were going to discontinue treatment because of treatment failure. The clinical non-responders either had an unchanged or increased exacerbation rate, or developed a secondary progressive course during GA treatment. Over more than one year, we prospectively collected 9 samples from clinical non-responders. We compared the immune response to GA of peripheral blood mononuclear cells from the 9 clinical non-responders with 15 clinical responders, using a standard proliferation assay combined with ELISPOT assays for detection of interferon-γ and interleukin-4 secreting cells. Thirteen (86{\%}) of the 15 clinical responders met at least 2 of the immunological response criteria mentioned above. In contrast, only 2 (22{\%}) of the 9 clinical nonresponders met two of the immunological criteria (p = 0.0006). We conclude that the ELISPOT assay may provide a promising additional tool for monitoring the treatment response in multiple sclerosis patients treated with GA.",
keywords = "Elispot assay, Glatiramer acetate, Multiple sclerosis",
author = "Cinthia Farina and Stefan Wagenpfeil and Reinhard Hohlfeld",
year = "2002",
doi = "10.1007/s00415-002-0904-0",
language = "English",
volume = "249",
pages = "1587--1592",
journal = "Journal of Neurology",
issn = "0340-5354",
publisher = "Dr. Dietrich Steinkopff Verlag GmbH and Co. KG",
number = "11",

}

TY - JOUR

T1 - Immunological assay for assessing the efficacy of glatiramer acetate (Copaxone) in multiple sclerosis

T2 - A pilot study

AU - Farina, Cinthia

AU - Wagenpfeil, Stefan

AU - Hohlfeld, Reinhard

PY - 2002

Y1 - 2002

N2 - Recently we described an enzyme-linked immunoadsorbent spot (ELISPOT) assay allowing us to define an immunological response profile observed in multiple sclerosis patients treated with Copaxone (glatiramer acetate; GA) but not untreated subjects [4]. The profile encompasses three criteria, a) reduced proliferative response to GA (as observed with a standard primary proliferation assay); b) strong in vitro activation of interferon-γ-producing T cells at high concentrations of GA (as detected by interferon-γ ELISPOT); and c) activation of interleukin-4-producing T cells over a wider range of concentrations of GA (as detected by interleukin-4 ELISPOT). It is at present unknown whether the immunological response to GA correlates with the clinical response. To address this question we performed the pilot study reported here. We asked the major German multiple sclerosis centres to send us blood samples from all GA-treated patients who were going to discontinue treatment because of treatment failure. The clinical non-responders either had an unchanged or increased exacerbation rate, or developed a secondary progressive course during GA treatment. Over more than one year, we prospectively collected 9 samples from clinical non-responders. We compared the immune response to GA of peripheral blood mononuclear cells from the 9 clinical non-responders with 15 clinical responders, using a standard proliferation assay combined with ELISPOT assays for detection of interferon-γ and interleukin-4 secreting cells. Thirteen (86%) of the 15 clinical responders met at least 2 of the immunological response criteria mentioned above. In contrast, only 2 (22%) of the 9 clinical nonresponders met two of the immunological criteria (p = 0.0006). We conclude that the ELISPOT assay may provide a promising additional tool for monitoring the treatment response in multiple sclerosis patients treated with GA.

AB - Recently we described an enzyme-linked immunoadsorbent spot (ELISPOT) assay allowing us to define an immunological response profile observed in multiple sclerosis patients treated with Copaxone (glatiramer acetate; GA) but not untreated subjects [4]. The profile encompasses three criteria, a) reduced proliferative response to GA (as observed with a standard primary proliferation assay); b) strong in vitro activation of interferon-γ-producing T cells at high concentrations of GA (as detected by interferon-γ ELISPOT); and c) activation of interleukin-4-producing T cells over a wider range of concentrations of GA (as detected by interleukin-4 ELISPOT). It is at present unknown whether the immunological response to GA correlates with the clinical response. To address this question we performed the pilot study reported here. We asked the major German multiple sclerosis centres to send us blood samples from all GA-treated patients who were going to discontinue treatment because of treatment failure. The clinical non-responders either had an unchanged or increased exacerbation rate, or developed a secondary progressive course during GA treatment. Over more than one year, we prospectively collected 9 samples from clinical non-responders. We compared the immune response to GA of peripheral blood mononuclear cells from the 9 clinical non-responders with 15 clinical responders, using a standard proliferation assay combined with ELISPOT assays for detection of interferon-γ and interleukin-4 secreting cells. Thirteen (86%) of the 15 clinical responders met at least 2 of the immunological response criteria mentioned above. In contrast, only 2 (22%) of the 9 clinical nonresponders met two of the immunological criteria (p = 0.0006). We conclude that the ELISPOT assay may provide a promising additional tool for monitoring the treatment response in multiple sclerosis patients treated with GA.

KW - Elispot assay

KW - Glatiramer acetate

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=0036460283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036460283&partnerID=8YFLogxK

U2 - 10.1007/s00415-002-0904-0

DO - 10.1007/s00415-002-0904-0

M3 - Article

VL - 249

SP - 1587

EP - 1592

JO - Journal of Neurology

JF - Journal of Neurology

SN - 0340-5354

IS - 11

ER -